Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:CYTK NASDAQ:TGTX NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$33.21+1.0%$36.29$23.23▼$39.95$1.05B0.65374,877 shs427,064 shsCYTKCytokinetics$58.96-6.1%$47.53$29.31▼$63.86$7.05B0.671.93 million shs2.14 million shsTGTXTG Therapeutics$34.87-0.5%$31.89$22.61▼$46.48$5.53B1.972.39 million shs1.90 million shsVKTXViking Therapeutics$34.73-1.1%$29.33$18.92▼$81.73$3.91B0.644.86 million shs4.48 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+2.21%-0.75%-5.84%+1.92%-14.66%CYTKCytokinetics+2.90%+3.26%+27.02%+61.48%+13.40%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%VKTXViking Therapeutics+6.26%+8.50%+45.85%+9.51%-46.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$33.21+1.0%$36.29$23.23▼$39.95$1.05B0.65374,877 shs427,064 shsCYTKCytokinetics$58.96-6.1%$47.53$29.31▼$63.86$7.05B0.671.93 million shs2.14 million shsTGTXTG Therapeutics$34.87-0.5%$31.89$22.61▼$46.48$5.53B1.972.39 million shs1.90 million shsVKTXViking Therapeutics$34.73-1.1%$29.33$18.92▼$81.73$3.91B0.644.86 million shs4.48 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+2.21%-0.75%-5.84%+1.92%-14.66%CYTKCytokinetics+2.90%+3.26%+27.02%+61.48%+13.40%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%VKTXViking Therapeutics+6.26%+8.50%+45.85%+9.51%-46.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3327.47% UpsideCYTKCytokinetics 2.76Moderate Buy$76.6429.99% UpsideTGTXTG Therapeutics 2.67Moderate Buy$49.0040.52% UpsideVKTXViking Therapeutics 2.86Moderate Buy$86.42148.82% UpsideCurrent Analyst Ratings BreakdownLatest COLL, CYTK, VKTX, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025CYTKCytokineticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TGTXTG TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/6/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$71.00 ➝ $82.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/2/2025CYTKCytokineticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$52.00 ➝ $56.009/29/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.009/29/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.009/27/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$707.01M1.48$12.72 per share2.61$7.10 per share4.68CYTKCytokinetics$85.74M82.29N/AN/A($1.15) per share-51.27TGTXTG Therapeutics$454.07M12.18$0.12 per share284.59$1.43 per share24.38VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0431.935.52N/A5.13%97.28%13.87%11/6/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3794.2434.87N/A13.31%26.05%9.58%11/3/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest COLL, CYTK, VKTX, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A11/5/2025Q3 2025CYTKCytokinetics-$1.59N/AN/AN/A$6.05 millionN/A11/3/2025Q3 2025TGTXTG Therapeutics$0.24N/AN/AN/A$152.12 millionN/A10/22/2025Q3 2025VKTXViking Therapeutics-$0.71N/AN/AN/AN/AN/A8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10CYTKCytokineticsN/A6.766.76TGTXTG Therapeutics0.893.862.96VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ACYTKCytokineticsN/ATGTXTG Therapeutics58.58%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%CYTKCytokinetics2.70%TGTXTG Therapeutics10.64%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableCYTKCytokinetics250119.66 million116.43 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableVKTXViking Therapeutics20112.45 million107.84 millionOptionableCOLL, CYTK, VKTX, and TGTX HeadlinesRecent News About These CompaniesRFG Advisory LLC Acquires 25,387 Shares of Viking Therapeutics, Inc. $VKTXOctober 16 at 4:48 AM | marketbeat.comViking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025October 15 at 4:05 PM | prnewswire.comViking Therapeutics (VKTX) Projected to Post Earnings on WednesdayOctober 15 at 2:35 AM | marketbeat.comViking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteOctober 14 at 6:51 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.5% - Should You Sell?October 14 at 5:40 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 1% - What's Next?October 13 at 5:57 PM | marketbeat.comIFP Advisors Inc Acquires 10,048 Shares of Viking Therapeutics, Inc. $VKTXOctober 13 at 6:08 AM | marketbeat.comM&A Speculation Fuels Volatility in Viking Therapeutics SharesOctober 12, 2025 | aktiencheck.deAViking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. ILOctober 12, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.1% - What's Next?October 10, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases New Stake in Viking Therapeutics, Inc. $VKTXOctober 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1% - Should You Buy?October 10, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2025 | americanbankingnews.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Moderate Buy" by BrokeragesOctober 9, 2025 | marketbeat.comViking Therapeutics' (VKTX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 2.6% - Here's WhyOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Here's WhyOctober 7, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.6% - Here's What HappenedOctober 6, 2025 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Up 15.1% After Acquisition Buzz and Analyst Focus on Its PipelineOctober 6, 2025 | finance.yahoo.comViking Therapeutics:Â A Speculative BuyOctober 4, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 6.6% - What's Next?October 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025COLL, CYTK, VKTX, and TGTX Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$33.21 +0.33 (+1.00%) Closing price 04:00 PM EasternExtended Trading$33.61 +0.40 (+1.20%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Cytokinetics NASDAQ:CYTK$58.96 -3.84 (-6.11%) Closing price 04:00 PM EasternExtended Trading$59.56 +0.59 (+1.01%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.TG Therapeutics NASDAQ:TGTX$34.87 -0.18 (-0.51%) Closing price 04:00 PM EasternExtended Trading$34.72 -0.15 (-0.43%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Viking Therapeutics NASDAQ:VKTX$34.73 -0.39 (-1.11%) Closing price 04:00 PM EasternExtended Trading$33.83 -0.90 (-2.61%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
